PSD 509

Drug Profile

PSD 509

Alternative Names: M5004; PSD509

Latest Information Update: 28 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metris Therapeutics
  • Developer Plethora Solutions
  • Class Nonsteroidal anti-inflammatories
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 25 Feb 2013 Discontinued - Phase-I for Pain in United Kingdom (Vaginal)
  • 24 Jan 2011 No development reported - Phase-I for Pain in United Kingdom (Vaginal)
  • 23 Nov 2007 PSD 509 is available for licensing worldwide (http://www.plethorasolutions.co.uk)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top